Y Intercept Hong Kong Ltd Purchases New Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Y Intercept Hong Kong Ltd purchased a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 71,103 shares of the company’s stock, valued at approximately $254,000. Y Intercept Hong Kong Ltd owned about 0.11% of Fulcrum Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. State Street Corp lifted its holdings in shares of Fulcrum Therapeutics by 61.4% in the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company’s stock valued at $5,998,000 after acquiring an additional 638,955 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at about $721,000. Centiva Capital LP bought a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at about $273,000. Braidwell LP purchased a new stake in Fulcrum Therapeutics in the 3rd quarter worth about $3,817,000. Finally, Verition Fund Management LLC purchased a new stake in Fulcrum Therapeutics in the 3rd quarter worth about $134,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

NASDAQ FULC opened at $4.23 on Thursday. The firm’s 50 day moving average price is $3.56 and its 200-day moving average price is $5.85. Fulcrum Therapeutics, Inc. has a 52-week low of $2.86 and a 52-week high of $13.70. The company has a market cap of $228.16 million, a PE ratio of -13.64 and a beta of 2.14.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on FULC. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $22.00 to $3.00 in a research report on Thursday, September 12th. Leerink Partners reissued a “market perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. HC Wainwright reissued a “neutral” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.